Carcinoma of the Thyroid Gland: Insights into Etiology, Pathogenesis, Diagnosis and Possible Lines of Management

Ahmed M. Kabel^{1, 2,} , Maaly A. Abd Elmaaboud² and Aliyah M. Marghalani³

¹Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia

²Pharmacology Department, Faculty of Medicine, Tanta University, Tanta, Egypt

³Pharm D, College of Pharmacy, Taif University, Taif, Saudi Arabia

Cite this paper:
Ahmed M. Kabel, Maaly A. Abd Elmaaboud and Aliyah M. Marghalani. Carcinoma of the Thyroid Gland: Insights into Etiology, Pathogenesis, Diagnosis and Possible Lines of Management. Journal of Cancer Research and Treatment. 2020; 8(1):7-10. doi: 10.12691/jcrt-8-1-2

Abstract

Thyroid carcinoma is one of the most common malignancies of the endocrine system worldwide. Over the recent years, there has been a significant increase in the newly reported cases of thyroid cancer which may be attributed to the wide use of imaging techniques in the diagnosis and treatment of a wide range of human diseases. Papillary thyroid cancer is the most common type of thyroid malignancies. Lines of treatment include total thyroidectomy, radioactive iodine therapy, and molecular-targeted therapies. Prognosis of thyroid carcinoma depend on many factors including age of the patient, the tumor type and its stage at the time of diagnosis of the disease. This review sheds light on carcinoma of the thyroid gland in view of the recent trends regarding its prevalence, risk factors, types, clinical picture, methods of diagnosis and possible lines of management.

Keywords:
carcinoma thyroid gland etiology pathogenesis diagnosis management

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Vaisman F, Corbo R, Vaisman M. Thyroid carcinoma in children and adolescents-systematic review of the literature. J Thyroid Res. 2011; 2011: 845362.
[2]	Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 2015; 8(1): 30-40.
[3]	Shah JP. Thyroid carcinoma: epidemiology, histology, and diagnosis. Clin Adv Hematol Oncol. 2015; 13(4 Suppl 4): 3-6.
[4]	Fagin JA, Wells SA Jr. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med. 2016; 375(11): 1054-1067.
[5]	Liu J, Wang Y, Da D, Zheng M. Hyperfunctioning thyroid carcinoma: A systematic review. Mol Clin Oncol. 2019; 11(6): 535-550.
[6]	Thomas CM, Asa SL, Ezzat S, Sawka AM, Goldstein D. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines. Curr Oncol. 2019; 26(5): 338-344.
[7]	Lamartina L, Grani G, Durante C, Filetti S. Recent advances in managing differentiated thyroid cancer. F1000Res. 2018; 7: 86.
[8]	Jayarangaiah A, Sidhu G, Brown J, et al. Therapeutic options for advanced thyroid cancer. Int J Clin Endocrinol Metab. 2019; 5(1): 26-34.
[9]	Kikuchi S, Perrier ND, Ituarte P, Siperstein AE, Duh QY, Clark OH. Latency period of thyroid neoplasia after radiation exposure. Ann Surg. 2004; 239(4): 536-543.
[10]	Younis E. Oncogenesis of Thyroid Cancer. Asian Pac J Cancer Prev. 2017; 18(5): 1191-1199.
[11]	Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2095-2128.
[12]	Popoveniuc G, Jonklaas J. Thyroid nodules. Med Clin North Am. 2012; 96(2): 329-349.
[13]	Enewold L, Harlan LC, Stevens JL, Sharon E. Thyroid cancer presentation and treatment in the United States. Ann Surg Oncol. 2015; 22(6): 1789-1797.
[14]	Schwaiger K, Koeninger F, Wimbauer J, Heinrich K, Gala-Kokalj A, Wechselberger G. Occult papillary thyroid cancer presenting as cystic metastasis of the lateral neck: A case report. Medicine (Baltimore). 2019; 98(30): e16659.
[15]	Delorme S, Raue F. Medullary Thyroid Carcinoma: Imaging. Recent Results Cancer Res. 2015; 204: 91-116.
[16]	Hoang JK, Branstetter BF 4th, Gafton AR, Lee WK, Glastonbury CM. Imaging of thyroid carcinoma with CT and MRI: approaches to common scenarios. Cancer Imaging. 2013; 13(1): 128-139.
[17]	Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated Thyroid Cancer-Treatment: State of the Art. Int J Mol Sci. 2017; 18(6): 1292.
[18]	Faugeras L, Pirson AS, Donckier J, et al. Refractory thyroid carcinoma: which systemic treatment to use?. Ther Adv Med Oncol. 2018; 10: 1758834017752853.
[19]	Kabel AM, Abd Elmaaboud MA. Cancer: Role of Nutrition, Pathogenesis, Diagnosis and Management. World Journal of Nutrition and Health 2014; 2(4): 48-51.
[20]	Wang TS, Sosa JA. Thyroid surgery for differentiated thyroid cancer - recent advances and future directions. Nat Rev Endocrinol. 2018; 14(11): 670-683.
[21]	Kovatch KJ, Hoban CW, Shuman AG. Thyroid cancer surgery guidelines in an era of de-escalation. Eur J Surg Oncol. 2018; 44(3): 297-306.
[22]	Jayarangaiah A, Sidhu G, Brown J, et al. Therapeutic options for advanced thyroid cancer. Int J Clin Endocrinol Metab. 2019; 5(1): 26-34.
[23]	Tang J, Kong D, Cui Q, et al. The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER. Onco Targets Ther. 2018; 11: 3551-3560.
[24]	Lee KJ, Chang SO, Jung KY. Experiences with a low-iodine diet: A qualitative study of patients with thyroid cancer receiving radioactive iodine therapy. Eur J Oncol Nurs. 2016; 23: 43-50.
[25]	Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid. 2010; 20(2): 135-146.
[26]	Lee MC, Kim MJ, Choi HS, et al. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer. Endocrinol Metab (Seoul). 2019; 34(2): 150-157.
[27]	Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer 2016; 23(4): R185-205.
[28]	Valerio L, Pieruzzi L, Giani C, Agate L, Bottici V, Lorusso L, et al. Targeted Therapy in Thyroid Cancer: State of the Art. Clin Oncol (R Coll Radiol) 2017; 29(5): 316-324.
[29]	Fleeman N, Houten R, Bagust A, et al. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Health Technol Assess. 2020; 24(2): 1-180.
[30]	Fleeman N, Houten R, Chaplin M, et al. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer. 2019; 19(1): 1209.
[31]	Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018; 36(1): 7-13.
[32]	Ferrari SM, Elia G, Ragusa F, et al. Novel treatments for anaplastic thyroid carcinoma. Gland Surg. 2020;9(Suppl 1): S28-S42.
[33]	Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A. Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients. World J Surg. 2018; 42(3): 615-622.
[34]	Hirsch D, Levy S, Tsvetov G, Gorshtein A, Slutzky-Shraga I, Akirov A, et al. Long-term outcomes and prognostic factors in patients with differentiated thyroid cancer and distant metastases. Endocr Pract. 2017; 23(10): 1193-1200.
[35]	Zhang TT, Li CF, Wen SS, et al. Effects of tumor size on prognosis in differentiated thyroid carcinoma smaller than 2 cm. Oncol Lett. 2019; 17(5): 4229-4236.